Adma Biologics (ADMA) Total Current Liabilities (2011 - 2026)
Adma Biologics' (ADMA) quarterly Total Current Liabilities came in at $69.5 million in Q4 2025, up 25.2% YoY from $55.5 million in Q4 2024, and up 23.1% on a QoQ basis from $56.5 million in Q3 2025.
Adma Biologics (ADMA) Total Current Liabilities (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Total Current Liabilities data on file, last reported at $69.5 million in Q4 2025.
- Quarterly Total Current Liabilities rose 25.2% year-over-year to $69.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $69.5 million (up 25.2% YoY) and the FY2025 annual result came in at $69.5 million, up 25.2% from the prior year.
- Total Current Liabilities rose to $69.5 million in Q4 2025, from $56.5 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $74.9 million in Q2 2025 to a low of $18.2 million in Q2 2021.
- A 5-year average of $43.4 million and a median of $43.1 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2021 — Total Current Liabilities jumped 96.3% — and 2023, when it decreased 5.85%.
- Tracing ADMA's Total Current Liabilities over 5 years: stood at $30.4 million in 2021, then increased by 29.26% to $39.3 million in 2022, then advanced by 26.84% to $49.8 million in 2023, then gained by 11.52% to $55.5 million in 2024, then climbed by 25.2% to $69.5 million in 2025.
- The last three Total Current Liabilities figures came in at $69.5 million (Q4 2025), $56.5 million (Q3 2025), and $74.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 75.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 75.76 Mn |
| Dec 31, 2025 | 69.54 Mn |
| Sep 30, 2025 | 56.49 Mn |
| Jun 30, 2025 | 74.94 Mn |
| Mar 31, 2025 | 53.50 Mn |
| Dec 31, 2024 | 55.54 Mn |
| Sep 30, 2024 | 44.90 Mn |
| Jun 30, 2024 | 44.18 Mn |
| Mar 31, 2024 | 53.09 Mn |
| Dec 31, 2023 | 49.81 Mn |
| Sep 30, 2023 | 41.84 Mn |
| Jun 30, 2023 | 41.95 Mn |
| Mar 31, 2023 | 36.73 Mn |
| Dec 31, 2022 | 39.27 Mn |
| Sep 30, 2022 | 44.44 Mn |
| Jun 30, 2022 | 28.07 Mn |
| Mar 31, 2022 | 31.57 Mn |
| Dec 31, 2021 | 30.38 Mn |
| Sep 30, 2021 | 32.34 Mn |
| Jun 30, 2021 | 18.19 Mn |